Article

How Psoriatic Arthritis Patients Rate Their Treatment

Biologic therapies for psoriasis and related diseases get high marks from patients. Guess what leads to dissatisfaction ...

Mercy KM, Gordon KB, Paller AS. Patient Satisfaction and Quality of Life in Psoriasis and Psoriatic ArthritisJAMA. 2014;312:2676-2677. doi:10.1001/jama.2014.12494.

Nearly half (45%) of all psoriatic arthritis patients express dissatisfaction with their treatment in surveys, say the expert authors of this review. And satisfaction is an important driver of adherence.

They outline some of the notable data on patient satisfaction from previous research. For instance:

•   Adverse effects and lack of effectiveness were primary reasons for discontinuing biological agents, but about 10% cited cost.

•  In the Netherlands, where patient dissatisfaction was only 10%-17%, and satisfaction scores were highest for patients getting biologic therapy, methotrexate or phototherapy, and lowest for patients receiving only topical therapies or acitretin.

•  Treatment of psoriasis with methotrexate or tumor necrosis factor inhibitors is associated with decreased cardiovascular morbidity and mortality.

A 2013 satisfaction survey published in JAMA Dermatology found that psoriatic arthritis was present in about half of respondents with severe psoriasis, a third with moderate psoriasis, and a quarter of those with mild psoriasis.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2025 MJH Life Sciences

All rights reserved.